CytoSorbents(CTSO) - 2024 Q1 - Quarterly Results

· Product Sales up a robust 14% over prior year, and a significant 22% sequentially · Enhanced profitability with gross margins that surged an absolute 8% to reach 76%, reflecting stronger operational ef iciencies · STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients · On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 Additionally, we expect to take deli ...